Barclays Maintains Equal-Weight on Pacira BioSciences, Lowers Price Target to $25
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Barclays analyst Glen Santangelo maintains Pacira BioSciences (NASDAQ:PCRX) with a Equal-Weight and lowers the price target from $27 to $25.
Barclays analyst Glen Santangelo maintains Pacira BioSciences (NASDAQ:PCRX) with a Equal-Weight and lowers the price target from $27 to $25.